Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy After ASCT for Hodgkin Lymphoma
NCT00070187Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Nov 2003
- Primary completion
- Jun 2005
- Modality
- Cytokines & Interferons, Peptides, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of cyclosporine, interferon gamma-1b and aldesleukin in Hodgkin lymphoma (HL) (2 arms), sponsored by Children's Oncology Group. Primary endpoints: Feasibility of immunotherapy, Toxicity of immunotherapy and 3 more. Started Nov 2003; status: completed.
02
Drugs
cyclosporineinterferon gamma-1baldesleukin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00070187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070187.